🏛️ Verified NIH Record • Updated 2026-05-12
Pain Reduction Using NEurostimulation Study (NCT05311956)
Delivery of an At-Home Nonpharmacologic Intervention (Transcranial Neurostimulation) to Mitigate Pain in Patients With End Stage Kidney Disease Receiving Hemodialysis
🔵 Active, Not Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Weill Medical College of Cornell University
🩺 Plain-English Summary (8th-Grade Level)
This is a 4-year project to see if a small battery-powered, device attached to a headband, that sits on the skin surface and delivers what is a hardly noticeable level of electrical stimulation can reduce pain in patients who receive hemodialysis on an ongoing basis.
Who can join: Review the eligibility criteria below.
Location: The Rogosin Institute — New York, New York
Age range: 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- The Rogosin Institute — New York, New York
- NewYork-Presbyterian - Weill Cornell Medicine — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in End Stage Kidney Disease
- Immunological Tolerance in Patients With Mismatched Kidney Transplants — Los Angeles, California
- Virtual Reality in Hemodialysis to Improve Psychological Well-being — Chicago, Illinois
- Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease — New York, New York
- Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants — San Dimas, California
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Decatur, Alabama
Explore by condition: All End Stage Kidney Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.